MYSummit Conference 2021
October 7-9, 2021, Edinburgh, UK
Radisson Blu Hotel
Eric Low Consultant MYELOMA360 Former CEO of Myeloma UK Edinburgh, UK
Eric has worked in the field of medical research charities for over 20 years. He founded Myeloma UK in 1996, leading the organisation as Chief Executive until 2017.
He currently runs a consultancy business specialising primarily in strategic market access, life sciences and healthcare policy, patient and patient group engagement.
Eric is committed and focused on improving patient outcomes and puts patients at the centre of everything he does. His goal is to have made a significant and material impact on the quality of life of patients and the prevention and curability of rare diseases. He has a strong track record of delivery and success in building multi-stakeholder research collaborations and consortia, and in delivering innovative solutions to complex issues, challenges and barriers standing in the way of progress.
Eric is also a Senior Visiting Research fellow at the University of Leeds Medical School, and he holds several Board, honorary, advisory and voluntary positions. He also advises numerous medical and health-focused charities on a pro bono basis. He was awarded an OBE for services to charity in the Queen’s Birthday Honours 2012.
Blake Morrison, PharmD
DEDICATED EXPERT IN NOVEL THERAPEUTICS DEVELOPMENT FOR MULTIPLE MYELOMA
Blake is an expert in multiple myeloma and has 30 years’ experience in the biopharmaceutical industry focus on the development of therapeutics associated with hematology.
He is a co-founder of MYELOMA360. In addition, he works at OncoTRACKER, Inc. a startup biotechnology company developing novel testing modalities for the management of multiple myeloma. He has held multiple leadership roles in strategic planning, product development, evidence generation, thought leader engagements, and scientific communications.
In his 22-year industry career, Blake has been directly associated with multiple agents used in the treatment and management of multiple myeloma, including:
- Zoledronic Acid (Zometa®)
- Bortezomib (VELCADE®)
- Lenalidomide (Revlimid®)
- Liposomal Doxorubicin (Doxil®)
- Carfilzomib (KYPROLIS®)
- Selinexor (XPOVIO®)
Additionally, he has development experience with several other approved products and investigational agents in multiple myeloma.
Blake has also worked in patient advocacy with the Multiple Myeloma Research Foundation (MMRF), involved with the CoMMpass Study and other outcomes related projects.
Blake graduated with his Doctor of Pharmacy from the University of the Pacific in Stockton, California and completed residencies in infectious diseases and oncology at University of California San Diego. Blake and family live in Emerald Hills, California located in the SF Bay Area.